Filing Analysis
CapsoVision, Inc. has entered into a Sales Agreement with Cantor Fitzgerald & Co. for an at-the-market (ATM) offering program. The program allows the company to sell up to $100,000,000 in common stock to raise capital.
🚩 Red Flags
- Potential for significant shareholder dilution due to the $100M ATM offering.
- ATM offerings are often used by micro-cap companies to fund immediate operational cash needs, which can signal liquidity pressure.
📋 Key Facts
- Entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. on August 13, 2026.
- The offering program is an 'at-the-market' (ATM) offering of common stock.
- The aggregate offering price is up to $100,000,000.
- The company filed a Form S-3 Registration Statement on August 13, 2026, to facilitate the sale.
- O’Melveny & Myers LLP provided a legal opinion regarding the validity of the shares.
CapsoVision, Inc. has entered into a $100 million at-the-market (ATM) equity offering agreement with Cantor Fitzgerald & Co. The filing also includes the company's financial results for the quarter ended June 30, 2026.
🚩 Red Flags
- Significant potential dilution: The $100M ATM program represents a large scale of capital raising which can lead to substantial shareholder dilution in micro-cap companies.
- Multiple items in one filing (ATM offering + Earnings release) often indicates a need for immediate liquidity alongside financial reporting.
📋 Key Facts
- Entered into a Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co. on August 13, 2026.
- The ATM program allows for the sale of common stock up to an aggregate price of $100,000,000.
- Cantor Fitzgerald will receive a cash commission of up to 3.0% of gross sales proceeds.
- Company intends to file a Registration Statement on Form S-3 to facilitate the offering.
- Released financial results for the fiscal quarter ended June 30, 2026.
CapsoVision, Inc. announced a change in its Board of Directors effective July 1, 2026. Dr. David S. Shields has been appointed as a Class I director and Compensation Committee member, filling the vacancy created by the resignation of Dr. Joanne Imperial.
🚩 Red Flags
- Board turnover (resignation of a director), though noted as non-dispute related.
📋 Key Facts
- Dr. David S. Shields appointed as Class I Director and Compensation Committee member effective July 1, 2026.
- Dr. Shields to receive $600 per hour for up to 3 hours per week under a new consulting agreement.
- Dr. Joanne Imperial resigned from the Board effective July 1, 2026; she will continue as an independent consultant.
- Dr. Imperial's amended consulting agreement includes compensation of $600 per hour for up to 5 hours per week and a grant of 10,000 stock options vesting over one year.
- The company stated Dr. Imperial's resignation was not due to any disagreement with management or the Board.
CapsoVision, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 11, 2026. Stockholders re-elected three Class I Directors and ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the 2026 fiscal year.
📋 Key Facts
- Annual Meeting of Stockholders held on June 11, 2026.
- Class I Directors re-elected: Joanne Imperial, M.D., Wen-Herng (Henry) King, and Michele Harari.
- Baker Tilly US, LLP ratified as independent registered public accounting firm for fiscal year 2026.
- Proposal #2 (auditor ratification) passed with 34,321,524 votes 'For' and only 154 votes 'Against'.
CapsoVision, Inc. reported its financial results for the first fiscal quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- Financial results were reported for the fiscal quarter ended March 31, 2026.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- A press release dated May 14, 2026, was furnished as Exhibit 99.1.
- The filing was signed by Kang-Huai (Johnny) Wang, President and CEO.
CapsoVision, Inc. issued a press release on March 26, 2026, announcing its financial results for the fiscal year ended December 31, 2025. The filing is a routine disclosure of results of operations and financial condition.
📋 Key Facts
- Announced financial results for the fiscal year ended December 31, 2025
- Press release dated March 26, 2026, was furnished as Exhibit 99.1
- The company is an emerging growth company as defined in Rule 405 of the Securities Act
- Common stock is listed on The Nasdaq Stock Market LLC under the ticker CV
CapsoVision raised $14 million through a private placement at a 5% discount while simultaneously announcing significant regulatory setbacks, including the abandonment of its first-generation CapsoCam Colon FDA submission.
🚩 Red Flags
- Regulatory failure: Abandonment of the first-generation product's FDA submission after agency pushback.
- FDA denial of Breakthrough Device Designation for pancreatic cancer screening.
- Multiple 8-K items (1.01, 2.02, 3.02, 7.01, 8.01) filed simultaneously, indicating significant corporate volatility.
- Discounted private placement (5% discount to closing price) suggests a need for immediate liquidity.
📋 Key Facts
- Entered into a Securities Purchase Agreement for a private placement of 2,867,089 shares at $4.883 per share.
- Total aggregate gross proceeds of approximately $14 million closed on March 16, 2026.
- Abandoned the 510(k) application for the first-generation CapsoCam Colon following FDA inquiries in December 2025 regarding image processing and study design.
- FDA denied a Breakthrough Device Designation for the CapsoCam UGI system in January 2026 due to lack of specific diagnostic criteria.
- Expected Q3 2026 submission for a second-generation CapsoCam Colon 510(k) application.
- Currently enrolled over 500 of 800 planned patients in a pivotal study for the second-generation device.
CapsoVision, Inc. entered into an amendment to its development agreement with Canon Inc., increasing the total development fee by $1 million. The increase covers enhanced features and specifications for CMOS image sensors used in the company's capsule endoscopy products.
🚩 Red Flags
- Increase in development costs by approximately 24% over the original $4.1 million estimate.
📋 Key Facts
- Amendment signed on March 9, 2026, with Canon Inc.
- The total development fee increased by $1 million from the original $4.1 million estimate.
- The development involves CMOS image sensors for capsule endoscopies aimed at obtaining FDA 510(k) clearance.
- The additional $1 million will be added to the 'remaining development fee' to be paid over time through unit price surcharges.
- Original agreement included a $1 million initial cash fee and a $3.1 million contingent fee.
CapsoVision, Inc. announced the submission of a 510(k) application to the FDA for its proprietary AI-assisted module for CapsoCam Plus®. This represents a regulatory milestone intended to enhance their existing product line through artificial intelligence integration.
📋 Key Facts
- Company submitted a 510(k) application to the FDA on December 29, 2025.
- The application is for an AI-assisted module designed for CapsoCam Plus®.
- The filing includes a press release as Exhibit 99.1.
CapsoVision, Inc. filed an 8-K to announce the release of its financial results for the fiscal quarter ended September 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Item 2.02).
- Financial results pertain to the fiscal quarter ending September 30, 2025.
- The company is an emerging growth company.
- Press release dated November 13, 2025, was furnished as Exhibit 99.1.
CapsoVision, Inc. announced the submission of a 510(k) FDA application for Breakthrough Device Designation regarding its Pancreatic Cancer Screening Capsule.
📋 Key Facts
- Company submitted a 510(k) FDA application on November 10, 2025.
- The application is specifically for 'Breakthrough Device Designation'.
- Target product: Pancreatic Cancer Screening Capsule.
CapsoVision, Inc. has appointed David Garcia as the new Principal Financial Officer (PFO) and Principal Accounting Officer (PAO), effective November 3, 2025.
📋 Key Facts
- David Garcia appointed as PFO and PAO effective November 3, 2025.
- Garcia previously served as VP of Financial Planning and Analysis at Matterport, Inc. (Oct 2020 - Oct 2025).
- Annual base salary set at $300,000 with a quarterly bonus of $12,500.
- Grant of stock options to purchase 165,000 shares under the 2025 Equity Incentive Plan; exercise price equals Nov 3, 2025 closing price.
- Vesting schedule: 25% on Nov 3, 2026; remaining 75% in 36 equal monthly installments thereafter.
CapsoVision, Inc. announced the planned retirement of Rebecca Petersen, Senior Director of Clinical Affairs, effective October 15, 2025. Keri Jorgenson has been promoted to Director of Clinical Operations to manage the transition.
🚩 Red Flags
- Departure of key clinical leadership in a highly regulated medical device sector.
📋 Key Facts
- Rebecca Petersen is retiring as Senior Director of Clinical Affairs on October 15, 2025.
- Keri Jorgenson (joined March 2022) is promoted to Director of Clinical Operations.
- Petersen will enter a consulting agreement starting October 16, 2025, at an hourly rate of $150.
- Unvested stock options for Petersen will continue to vest per existing schedules during the transition.
CapsoVision, Inc. announced the departure of its Chief Financial Officer, Kevin Lundquist, effective August 27, 2025. The company has initiated a search for a successor and has entered into a separation and consulting agreement with Mr. Lundquist.
🚩 Red Flags
- Sudden departure of a key C-suite executive (CFO) in a micro-cap environment can signal internal friction or financial reporting concerns, though the 'mutual' nature and consulting agreement suggest a managed transition.
📋 Key Facts
- Kevin Lundquist stepped down as CFO on August 27, 2025.
- The departure is characterized as a mutual agreement involving a Separation Agreement and a Consulting Agreement.
- Severance includes six months of base salary and a prorated annual bonus of $33,333.33.
- 86,806 unvested stock options will undergo accelerated vesting and remain exercisable until September 1, 2028.
- Mr. Lundquist will provide consulting assistance and transition support for up to six months (until February 28, 2026).
CapsoVision, Inc. filed an 8-K to announce the issuance of its financial results for the fiscal quarter ended June 30, 2025.
📋 Key Facts
- The filing is a standard announcement of quarterly financial results (Item 2.02).
- Financial results pertain to the fiscal quarter ended June 30, 2025.
- The press release containing the detailed results was issued on August 14, 2025.
CapsoVision entered into a development agreement with Canon Inc. to develop CMOS image sensors for future capsule endoscopy products, involving approximately $4.1 million in fees. Additionally, underwriters exercised an over-allotment option in the company's recent IPO, resulting in net proceeds of approximately $600,000.
🚩 Red Flags
- Contingent liability: The $3.1 million payment is tied to future sensor deliveries and will increase the cost of goods sold (COGS) via higher unit prices.
📋 Key Facts
- Entered into a development agreement with Canon Inc. on July 15, 2025.
- Total development fee to Canon is approximately $4.1 million ($1M upfront in cash; $3.1M contingent on delivery/performance).
- The remaining $3.1 million will be paid over time via an increased unit price under a future master purchase agreement.
- Underwriters exercised an option to purchase 129,978 additional shares of common stock on July 16, 2025.
- Net proceeds from the over-allotment exercise were approximately $600,000.
CapsoVision, Inc. completed a public offering of 5,500,000 shares of common stock at $5.00 per share, resulting in gross proceeds of $27.5 million. The transaction included an over-allotment option and the issuance of warrants to underwriters.
🚩 Red Flags
- Significant dilution: Issuance of 5.5 million new shares at $5.00 per share.
- Warrant overhang: Underwriters received warrants for 165,000 shares which may cause future dilution.
- Lock-up period: 6-month restriction on insiders/major stockholders.
📋 Key Facts
- Public offering of 5,500,000 shares of common stock at $5.00 per share.
- Gross proceeds totaled $27.5 million before discounts and expenses.
- Underwriters: The Benchmark Company, LLC and Roth Capital Partners, LLC.
- Over-allotment option for an additional 825,000 shares (15% of the offering).
- Issuance of warrants to underwriters for 165,000 shares at an exercise price of $6.25.
- Lock-up agreements signed by officers, directors, and certain stockholders for 6 months.
- Amended and restated Certificate of Incorporation and Bylaws became effective on July 3, 2025.